{"id":61047,"date":"2024-02-28T07:22:30","date_gmt":"2024-02-28T07:22:30","guid":{"rendered":"https:\/\/medsname.com\/hytrin\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"hytrin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/hytrin\/","title":{"rendered":"Hytrin"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Hytrin?<\/h3>\n

Hytrin<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 1 \/ 2 \/ 5 mg Terazosin tablet<\/strong> from AbbVie — a long-acting selective alpha-1 adrenergic receptor antagonist (quinazoline)<\/strong>, \u03b4\u03c1\u03ce\u03bd\u03c4\u03b1\u03c2 \u03c3\u03b5 post-synaptic alpha-1 adrenergic receptors on arterial smooth muscle and on prostatic\/bladder-neck smooth muscle<\/strong>. Terazosin was introduced by Abbott (now AbbVie) in 1987 as Hytrin<\/strong> — developed as a longer-acting successor to prazosin, with a 12-hour half-life that permits once-daily dosing. Structurally a close quinazoline analogue of prazosin. Widely used in the 1990s and 2000s for benign prostatic hyperplasia (BPH) and as an add-on antihypertensive; partially displaced by the prostate-selective alpha-1A blockers (tamsulosin, silodosin) for BPH-only use, but retains a strong position where coexisting hypertension makes a non-selective alpha-blocker appropriate. Half-life 12 hours (once-daily dosing appropriate); onset 1-2 hours; peak 1-2 hours; symptomatic BPH benefit typically at 2-4 weeks. Primary indications: benign prostatic hyperplasia, resistant hypertension as add-on agent<\/strong>. \u03a4\u03c5\u03c0\u03b9\u03ba\u03ae \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1: \u03a5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7:<\/strong> start 1 mg at bedtime (first-dose phenomenon risk), titrate every 1-2 weeks up to 5-20 mg\/day. The longer half-life vs prazosin makes once-daily dosing practical. \u0394\u03b5\u03bd \u03b5\u03af\u03bd\u03b1\u03b9 \u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 \u03b1\u03bd\u03c4\u03b9\u03c5\u03c0\u03b5\u03c1\u03c4\u03b1\u03c3\u03b9\u03ba\u03cc.<\/strong> ALLHAT stopped the doxazosin arm early for excess HF; terazosin is extrapolated to the same class concern. Reserve for fourth\/fifth-line use, especially where BPH coexists. \u03a0\u03ac\u03bd\u03c4\u03b1 \u03be\u03b5\u03ba\u03b9\u03bd\u03ae\u03c3\u03c4\u03b5 \u03c4\u03b7\u03bd \u03c0\u03c1\u03ce\u03c4\u03b7 \u03b4\u03cc\u03c3\u03b7 \u03c0\u03c1\u03b9\u03bd \u03c4\u03bf\u03bd \u03cd\u03c0\u03bd\u03bf<\/strong> \u2014 \u03c4\u03bf \u03c6\u03b1\u03b9\u03bd\u03cc\u03bc\u03b5\u03bd\u03bf \u03c4\u03b7\u03c2 \u201c\u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b4\u03cc\u03c3\u03b7\u03c2\u201d \u03c0\u03c1\u03bf\u03ba\u03b1\u03bb\u03b5\u03af \u03c3\u03bf\u03b2\u03b1\u03c1\u03ae \u03bf\u03c1\u03b8\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03bf\u03c0\u03c4\u03ce\u03c3\u03b7 \u03c4\u03b9\u03c2 \u03c0\u03c1\u03ce\u03c4\u03b5\u03c2 \u03ce\u03c1\u03b5\u03c2. \u0394\u03b5\u03bd \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03bd\u03c4\u03c5\u03c0\u03b5\u03c1\u03c4\u03b1\u03c3\u03b9\u03ba\u03cc \u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 (\u03b1\u03bd\u03b7\u03c3\u03c5\u03c7\u03af\u03b5\u03c2 \u03ba\u03bb\u03ac\u03c3\u03b7\u03c2 ALLHAT) \u2014 \u03ba\u03c1\u03b1\u03c4\u03ae\u03c3\u03c4\u03b5 \u03b3\u03b9\u03b1 \u03c7\u03c1\u03ae\u03c3\u03b7 \u03c9\u03c2 \u03c4\u03ad\u03c4\u03b1\u03c1\u03c4\u03b7\/\u03c0\u03ad\u03bc\u03c0\u03c4\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae, \u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u03cc\u03c4\u03b1\u03bd \u03c3\u03c5\u03bd\u03c5\u03c0\u03ac\u03c1\u03c7\u03b5\u03b9 BPH. \u0393\u03b9\u03b1 \u03c4\u03bf\u03c5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03bf\u03c5\u03c2 \u03c5\u03c0\u03b5\u03c1\u03c4\u03b1\u03c3\u03b9\u03ba\u03bf\u03cd\u03c2 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2, \u03b7 \u03c3\u03cd\u03b3\u03c7\u03c1\u03bf\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03be\u03b5\u03ba\u03b9\u03bd\u03ac \u03bc\u03b5 \u03ad\u03bd\u03b1\u03bd \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE\/ARB, \u03ad\u03bd\u03b1 \u03b1\u03bd\u03c4\u03b9\u03b1\u03b3\u03c9\u03bd\u03b9\u03c3\u03c4\u03ae \u03b1\u03c3\u03b2\u03b5\u03c3\u03c4\u03af\u03bf\u03c5, \u03ad\u03bd\u03b1 \u03b8\u03b5\u03b9\u03b1\u03b6\u03b9\u03b4\u03b9\u03ba\u03cc \u03ba\u03b1\u03b9 \u03c3\u03c0\u03b9\u03c1\u03bf\u03bd\u03bf\u03bb\u03b1\u03ba\u03c4\u03cc\u03bd\u03b7 \u03c0\u03c1\u03b9\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03c3\u03b5 \u03b1-\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 \u03ae \u03ba\u03b5\u03bd\u03c4\u03c1\u03b9\u03ba\u03ac \u03b4\u03c1\u03ce\u03bd\u03c4\u03b1 \u03c0\u03b1\u03c1\u03ac\u03b3\u03bf\u03bd\u03c4\u03b1.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

What Is Hytrin?<\/h2>\n

Hytrin is an oral 1 \/ 2 \/ 5 mg Terazosin tablet from AbbVie, supplied in 30-180 tablets. Terazosin was introduced by Abbott (now AbbVie) in 1987 as Hytrin<\/strong> — developed as a longer-acting successor to prazosin, with a 12-hour half-life that permits once-daily dosing. Structurally a close quinazoline analogue of prazosin. Widely used in the 1990s and 2000s for benign prostatic hyperplasia (BPH) and as an add-on antihypertensive; partially displaced by the prostate-selective alpha-1A blockers (tamsulosin, silodosin) for BPH-only use, but retains a strong position where coexisting hypertension makes a non-selective alpha-blocker appropriate.<\/p>\n

How Terazosin Works<\/h2>\n

Terazosin acts on post-synaptic alpha-1 adrenergic receptors on arterial smooth muscle and on prostatic\/bladder-neck smooth muscle<\/strong>. \u039f\u03b9 \u03b5\u03c0\u03b1\u03ba\u03cc\u03bb\u03bf\u03c5\u03b8\u03b5\u03c2 \u03b5\u03c0\u03b9\u03c0\u03c4\u03ce\u03c3\u03b5\u03b9\u03c2:<\/p>\n

    \n
  • \u0391\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03ba\u03b1\u03b9 \u03c6\u03bb\u03b5\u03b2\u03b9\u03ba\u03ae \u03b4\u03b9\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae<\/strong> \u2014 \u03bf \u03b1\u03c0\u03bf\u03ba\u03bb\u03b5\u03b9\u03c3\u03bc\u03cc\u03c2 \u03c4\u03c9\u03bd \u03b1-1 \u03c5\u03c0\u03bf\u03b4\u03bf\u03c7\u03ad\u03c9\u03bd \u03c3\u03c4\u03bf\u03c5\u03c2 \u03bb\u03b5\u03af\u03bf\u03c5\u03c2 \u03bc\u03cd\u03b5\u03c2 \u03c4\u03c9\u03bd \u03b1\u03b3\u03b3\u03b5\u03af\u03c9\u03bd \u03bc\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03b7\u03bd \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03c4\u03af\u03c3\u03c4\u03b1\u03c3\u03b7\u00b7 \u03b7 \u03c6\u03bb\u03b5\u03b2\u03b9\u03ba\u03ae \u03b4\u03b9\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae \u03bc\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03bf \u03c0\u03c1\u03bf\u03c6\u03cc\u03c1\u03c4\u03b9\u03bf<\/li>\n
  • \u039c\u03b5\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf\u03c2 \u03c4\u03cc\u03bd\u03bf\u03c2 \u03c4\u03c9\u03bd \u03bb\u03b5\u03af\u03c9\u03bd \u03bc\u03c5\u03ce\u03bd \u03c4\u03b7\u03c2 \u03bf\u03c5\u03c1\u03bf\u03b4\u03cc\u03c7\u03bf\u03c5 \u03ba\u03cd\u03c3\u03c4\u03b7\u03c2 \u03ba\u03b1\u03b9 \u03c4\u03bf\u03c5 \u03c0\u03c1\u03bf\u03c3\u03c4\u03ac\u03c4\u03b7<\/strong> \u2014 \u03b2\u03b5\u03bb\u03c4\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03b7 \u03c1\u03bf\u03ae \u03c4\u03c9\u03bd \u03bf\u03cd\u03c1\u03c9\u03bd \u03c3\u03c4\u03b7\u03bd BPH (\u03ba\u03c5\u03c1\u03af\u03b1\u03c1\u03c7\u03b7 \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u03b5\u03c0\u03af\u03b4\u03c1\u03b1\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03c4\u03b9\u03c2 XL\/\u03bc\u03b1\u03ba\u03c1\u03ac\u03c2 \u03b4\u03c1\u03ac\u03c3\u03b7\u03c2 \u03bc\u03bf\u03c1\u03c6\u03ad\u03c2)<\/li>\n
  • \u0392\u03b5\u03bb\u03c4\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf \u03bb\u03b9\u03c0\u03b9\u03b4\u03b1\u03b9\u03bc\u03b9\u03ba\u03cc \u03c0\u03c1\u03bf\u03c6\u03af\u03bb<\/strong> \u2014 \u03bc\u03ad\u03c4\u03c1\u03b9\u03b1 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03c4\u03bf\u03c5 LDL \u03ba\u03b1\u03b9 \u03c4\u03c9\u03bd \u03c4\u03c1\u03b9\u03b3\u03bb\u03c5\u03ba\u03b5\u03c1\u03b9\u03b4\u03af\u03c9\u03bd, \u03bc\u03b9\u03ba\u03c1\u03ae \u03b1\u03cd\u03be\u03b7\u03c3\u03b7 \u03c4\u03bf\u03c5 HDL\u00b7 \u03bc\u03b5\u03c4\u03b1\u03b2\u03bf\u03bb\u03b9\u03ba\u03ac \u03b4\u03b9\u03b1\u03c6\u03bf\u03c1\u03b5\u03c4\u03b9\u03ba\u03cc \u03b1\u03c0\u03cc \u03c4\u03b1 \u03b8\u03b5\u03b9\u03b1\u03b6\u03af\u03b4\u03b9\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03b1 \u03b2-\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2<\/li>\n
  • \u0392\u03b5\u03bb\u03c4\u03b9\u03c9\u03bc\u03ad\u03bd\u03b7 \u03b5\u03c5\u03b1\u03b9\u03c3\u03b8\u03b7\u03c3\u03af\u03b1 \u03c3\u03c4\u03b7\u03bd \u03b9\u03bd\u03c3\u03bf\u03c5\u03bb\u03af\u03bd\u03b7<\/strong> \u03c3\u03b5 \u03bf\u03c1\u03b9\u03c3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b5\u03c2 \u2014 \u03ad\u03bd\u03b1 \u03b5\u03c0\u03b9\u03c7\u03b5\u03af\u03c1\u03b7\u03bc\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03bf\u03c5\u03c2 \u03b1-\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 \u03c3\u03b5 \u03c5\u03c0\u03b5\u03c1\u03c4\u03b1\u03c3\u03b9\u03ba\u03bf\u03cd\u03c2 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03bc\u03b5\u03c4\u03b1\u03b2\u03bf\u03bb\u03b9\u03ba\u03cc \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03ae \u03b4\u03b9\u03b1\u03b2\u03ae\u03c4\u03b7 \u03c4\u03cd\u03c0\u03bf\u03c5 2<\/li>\n
  • \u039a\u03b1\u03bc\u03af\u03b1 \u03ac\u03bc\u03b5\u03c3\u03b7 \u03b5\u03c0\u03af\u03b4\u03c1\u03b1\u03c3\u03b7 \u03c3\u03c4\u03b7 \u03c1\u03b5\u03bd\u03af\u03bd\u03b7 \u03ae \u03c3\u03c4\u03b1 \u03b7\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03bb\u03cd\u03c4\u03b5\u03c2<\/strong> \u2014 \u03c4\u03bf \u03ba\u03ac\u03bb\u03b9\u03bf, \u03c4\u03bf \u03bd\u03ac\u03c4\u03c1\u03b9\u03bf \u03ba\u03b1\u03b9 \u03b7 \u03ba\u03c1\u03b5\u03b1\u03c4\u03b9\u03bd\u03af\u03bd\u03b7 \u03b4\u03b5\u03bd \u03b5\u03c0\u03b7\u03c1\u03b5\u03ac\u03b6\u03bf\u03bd\u03c4\u03b1\u03b9 (\u03c3\u03b5 \u03b1\u03bd\u03c4\u03af\u03b8\u03b5\u03c3\u03b7 \u03bc\u03b5 \u03c4\u03b1 \u03b4\u03b9\u03bf\u03c5\u03c1\u03b7\u03c4\u03b9\u03ba\u03ac \u03ba\u03b1\u03b9 \u03c4\u03bf\u03c5\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 RAAS)<\/li>\n
  • \u0391\u03bd\u03b1\u03ba\u03bb\u03b1\u03c3\u03c4\u03b9\u03ba\u03ae \u03c4\u03b1\u03c7\u03c5\u03ba\u03b1\u03c1\u03b4\u03af\u03b1<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03bc\u03b5\u03b9\u03c9\u03bc\u03ad\u03bd\u03b7 \u03c3\u03b5 \u03c3\u03cd\u03b3\u03ba\u03c1\u03b9\u03c3\u03b7 \u03bc\u03b5 \u03c4\u03bf\u03c5\u03c2 \u03ac\u03bc\u03b5\u03c3\u03bf\u03c5\u03c2 \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03b4\u03b9\u03b1\u03c3\u03c4\u03b1\u03bb\u03c4\u03b9\u03ba\u03bf\u03cd\u03c2 (\u03c5\u03b4\u03c1\u03b1\u03bb\u03b1\u03b6\u03af\u03bd\u03b7, \u03bc\u03b9\u03bd\u03bf\u03be\u03b9\u03b4\u03af\u03bb\u03b7) \u03bb\u03cc\u03b3\u03c9 \u03ba\u03ac\u03c0\u03bf\u03b9\u03b1\u03c2 \u03ba\u03b5\u03bd\u03c4\u03c1\u03b9\u03ba\u03ae\u03c2 \u03c3\u03c5\u03bc\u03c0\u03b1\u03b8\u03b7\u03c4\u03b9\u03ba\u03ae\u03c2 \u03b1\u03bd\u03ac\u03b4\u03c1\u03b1\u03c3\u03b7\u03c2, \u03b1\u03bb\u03bb\u03ac \u03b5\u03be\u03b1\u03ba\u03bf\u03bb\u03bf\u03c5\u03b8\u03b5\u03af \u03bd\u03b1 \u03b5\u03bc\u03c6\u03b1\u03bd\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7\u03bd \u03ad\u03bd\u03b1\u03c1\u03be\u03b7<\/li>\n<\/ul>\n

    \u0395\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03b1\u03b9 \u0392\u03b1\u03c3\u03b9\u03c3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c3\u03b5 \u0391\u03c0\u03bf\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03a7\u03c1\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
      \n
    • Benign prostatic hyperplasia, resistant hypertension as add-on agent<\/strong><\/li>\n
    • \u039a\u03b1\u03bb\u03bf\u03ae\u03b8\u03b7\u03c2 \u03c5\u03c0\u03b5\u03c1\u03c0\u03bb\u03b1\u03c3\u03af\u03b1 \u03c0\u03c1\u03bf\u03c3\u03c4\u03ac\u03c4\u03b7<\/strong> — primary indication; once-daily convenience<\/li>\n
    • \u0391\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7<\/strong> as fourth\/fifth-line add-on, especially where BPH coexists<\/li>\n<\/ul>\n

      \u039a\u03c5\u03c1\u03af\u03b1\u03c1\u03c7\u03b5\u03c2 \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ad\u03c2 \u03b4\u03bf\u03ba\u03b9\u03bc\u03ad\u03c2:<\/strong> HYTRIN Community Assessment Trial (HYCAT, 1996)<\/strong> — terazosin improved IPSS by 37% in 2,084 men with symptomatic BPH over 1 year. VA Cooperative BPH Trial (Lepor, NEJM 1996)<\/strong> — terazosin + finasteride no better than terazosin alone in men with smaller prostates, foreshadowing the MTOPS finding that combination therapy helps larger prostates. \u039f\u03bc\u03ac\u03b4\u03b1 doxazosin \u03c4\u03b7\u03c2 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7\u03c2 ALLHAT (2000)<\/strong> — class-level HF signal.<\/p>\n

      Hytrin Dosage<\/h2>\n

      \u039a\u03cd\u03c1\u03b9\u03b1 \u03b4\u03cc\u03c3\u03b7:<\/strong> \u03a5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7:<\/strong> start 1 mg at bedtime (first-dose phenomenon risk), titrate every 1-2 weeks up to 5-20 mg\/day. The longer half-life vs prazosin makes once-daily dosing practical. \u0394\u03b5\u03bd \u03b5\u03af\u03bd\u03b1\u03b9 \u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 \u03b1\u03bd\u03c4\u03b9\u03c5\u03c0\u03b5\u03c1\u03c4\u03b1\u03c3\u03b9\u03ba\u03cc.<\/strong> ALLHAT stopped the doxazosin arm early for excess HF; terazosin is extrapolated to the same class concern. Reserve for fourth\/fifth-line use, especially where BPH coexists.<\/p>\n

      \u0386\u03bb\u03bb\u03b5\u03c2 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2:<\/strong> \u039a\u03b1\u03bb\u03bf\u03ae\u03b8\u03b7\u03c2 \u03c5\u03c0\u03b5\u03c1\u03c0\u03bb\u03b1\u03c3\u03af\u03b1 \u03c0\u03c1\u03bf\u03c3\u03c4\u03ac\u03c4\u03b7:<\/strong> start 1 mg at bedtime, titrate to 5-10 mg once daily over 2-4 weeks. Dose at bedtime indefinitely to minimise orthostatic effects. Symptom benefit typically clear by 4-6 weeks; if inadequate, switch to or add a prostate-selective alpha-1A blocker (tamsulosin) or a 5-alpha-reductase inhibitor (finasteride) for larger prostates (>40 g).<\/p>\n

      \u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7:<\/strong> take once daily at bedtime. Food does not significantly affect absorption.<\/p>\n

      \u03a0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7\u03c2:<\/strong><\/p>\n

        \n
      • \u0392\u03b1\u03c3\u03b9\u03ba\u03ae \u03b1\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7:<\/strong> \u03c3\u03c6\u03c5\u03b3\u03bc\u03b9\u03ba\u03ae \u03c0\u03af\u03b5\u03c3\u03b7 \u03c3\u03b5 \u03cd\u03c0\u03c4\u03b9\u03b1 \u03ba\u03b1\u03b9 \u03cc\u03c1\u03b8\u03b9\u03b1 \u03b8\u03ad\u03c3\u03b7 (\u03ba\u03b1\u03c4\u03b1\u03b3\u03c1\u03ac\u03c8\u03c4\u03b5 \u03bf\u03c1\u03b8\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03ae \u03c0\u03c4\u03ce\u03c3\u03b7), \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03cc \u03c1\u03c5\u03b8\u03bc\u03cc, \u03b1\u03bd\u03b1\u03c3\u03ba\u03cc\u03c0\u03b7\u03c3\u03b7 \u03c3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u03b3\u03b9\u03b1 \u03b6\u03ac\u03bb\u03b7\/\u03c0\u03c4\u03ce\u03c3\u03b5\u03b9\u03c2, \u03ba\u03b1\u03c4\u03ac\u03bb\u03bf\u03b3\u03bf\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd (\u03b5\u03bb\u03ad\u03b3\u03be\u03c4\u03b5 \u03b3\u03b9\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03c0\u03bf\u03c5 \u03b1\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03bf\u03cd\u03bd).<\/li>\n
      • \u0395\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b1 1-2:<\/strong> \u03b5\u03c0\u03b1\u03bd\u03ac\u03bb\u03b7\u03c8\u03b7 \u03bc\u03ad\u03c4\u03c1\u03b7\u03c3\u03b7\u03c2 \u03b1\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae\u03c2 \u03c0\u03af\u03b5\u03c3\u03b7\u03c2 (\u03cd\u03c0\u03c4\u03b9\u03b1 \u03ba\u03b1\u03b9 \u03cc\u03c1\u03b8\u03b9\u03b1 \u03c3\u03c4\u03ac\u03c3\u03b7), \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae\u03c2 \u03c3\u03c5\u03c7\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2, \u03b1\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7 \u03c3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd. \u03a0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae \u03b4\u03cc\u03c3\u03b7\u03c2 \u03c0\u03c1\u03bf\u03c2 \u03c4\u03b1 \u03c0\u03ac\u03bd\u03c9 \u03ae \u03ba\u03ac\u03c4\u03c9 \u03bc\u03b5 \u03b2\u03ac\u03c3\u03b7 \u03c4\u03b7\u03bd \u03b1\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03c0\u03af\u03b5\u03c3\u03b7 \u03ba\u03b1\u03b9 \u03c4\u03b7\u03bd \u03b1\u03bd\u03bf\u03c7\u03ae.<\/li>\n
      • \u0395\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b1 4-6:<\/strong> \u03b1\u03be\u03b9\u03bf\u03bb\u03bf\u03b3\u03ae\u03c3\u03c4\u03b5 \u03c4\u03b7\u03bd \u03c3\u03c4\u03cc\u03c7\u03bf\u03c2 \u03c0\u03af\u03b5\u03c3\u03b7\u03c2\u00b7 \u03c4\u03bf \u03b2\u03ac\u03c1\u03bf\u03c2 \u03c4\u03c9\u03bd \u03c3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd\u00b7 \u03b5\u03bb\u03ad\u03b3\u03be\u03c4\u03b5 \u03b3\u03b9\u03b1 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c3\u03b5 \u03c3\u03c5\u03bc\u03c0\u03c4\u03ce\u03bc\u03b1\u03c4\u03b1 \u039a\u03a5\u03a0 \u03b5\u03ac\u03bd \u03b9\u03c3\u03c7\u03cd\u03b5\u03b9 (IPSS).<\/li>\n
      • \u03a3\u03c5\u03bd\u03b5\u03c7\u03ae\u03c2 \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7:<\/strong> \u03b5\u03c4\u03ae\u03c3\u03b9\u03b1 \u03b1\u03bd\u03b1\u03c3\u03ba\u03cc\u03c0\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03c0\u03af\u03b5\u03c3\u03b7\u03c2 \u03b1\u03af\u03bc\u03b1\u03c4\u03bf\u03c2, \u03b9\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03cc \u03c0\u03c4\u03ce\u03c3\u03b5\u03c9\u03bd\/\u03c3\u03c5\u03b3\u03ba\u03bf\u03c0\u03ae\u03c2, \u03b9\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03cc \u03ba\u03b1\u03c4\u03b1\u03c1\u03c1\u03ac\u03ba\u03c4\u03b7 (\u03c0\u03c1\u03bf\u03b5\u03b9\u03b4\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03c7\u03b1\u03bb\u03b1\u03c1\u03ae \u03af\u03c1\u03b9\u03b4\u03b1 \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03b5\u03b3\u03c7\u03b5\u03af\u03c1\u03b7\u03c3\u03b7).<\/li>\n
      • \u0394\u03b9\u03b1\u03ba\u03bf\u03c0\u03ae \u03ae \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03b4\u03cc\u03c3\u03b7\u03c2 \u03c3\u03b5 \u03c0\u03b5\u03c1\u03af\u03c0\u03c4\u03c9\u03c3\u03b7:<\/strong> \u03c3\u03c5\u03b3\u03ba\u03bf\u03c0\u03ae, \u03c0\u03c4\u03ce\u03c3\u03b5\u03b9\u03c2, \u03c0\u03c1\u03b9\u03ac\u03c0\u03b9\u03c3\u03bc\u03bf\u03c2, \u03b1\u03bd\u03b1\u03b3\u03bd\u03ce\u03c1\u03b9\u03c3\u03b7 \u03c7\u03b1\u03bb\u03b1\u03c1\u03ae\u03c2 \u03af\u03c1\u03b9\u03b4\u03b1\u03c2, \u03c3\u03bf\u03b2\u03b1\u03c1\u03ae \u03bf\u03c0\u03b9\u03c3\u03b8\u03bf\u03b4\u03c1\u03bf\u03bc\u03b9\u03ba\u03ae \u03b5\u03ba\u03c3\u03c0\u03b5\u03c1\u03bc\u03ac\u03c4\u03b9\u03c3\u03b7 \u03c0\u03bf\u03c5 \u03b5\u03c0\u03b7\u03c1\u03b5\u03ac\u03b6\u03b5\u03b9 \u03c4\u03b7\u03bd \u03c0\u03bf\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1 \u03b6\u03c9\u03ae\u03c2.<\/li>\n<\/ul>\n

        \u0394\u03b9\u03b1\u03ba\u03bf\u03c0\u03ae:<\/strong> \u03c7\u03c9\u03c1\u03af\u03c2 \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c6\u03bf\u03c1\u03ac\u03c2. \u039f\u03b9 \u03b1\u03c0\u03bb\u03ac \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 \u03bc\u03c0\u03bf\u03c1\u03bf\u03cd\u03bd \u03bd\u03b1 \u03b4\u03b9\u03b1\u03ba\u03bf\u03c0\u03bf\u03cd\u03bd, \u03b1\u03bb\u03bb\u03ac \u03b1\u03bd\u03b1\u03bc\u03ad\u03bd\u03b5\u03c4\u03b1\u03b9 \u03ba\u03ac\u03c0\u03bf\u03b9\u03b1 \u03b1\u03cd\u03be\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03c0\u03af\u03b5\u03c3\u03b7\u03c2 \u03b1\u03bd \u03c3\u03c5\u03bd\u03ad\u03b2\u03b1\u03bb\u03b1\u03bd \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac \u03c3\u03c4\u03bf\u03bd \u03ad\u03bb\u03b5\u03b3\u03c7\u03bf. \u0395\u03c0\u03b1\u03bd\u03b5\u03ba\u03ba\u03b9\u03bd\u03ae\u03c3\u03c4\u03b5 \u03c3\u03c4\u03b7 \u03b4\u03cc\u03c3\u03b7 \u03ad\u03bd\u03b1\u03c1\u03be\u03b7\u03c2 (\u03cc\u03c7\u03b9 \u03c3\u03c4\u03b7\u03bd \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b4\u03cc\u03c3\u03b7 \u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7\u03c2) \u03b1\u03bd \u03b5\u03c0\u03b1\u03bd\u03b5\u03ba\u03ba\u03b9\u03bd\u03b5\u03af\u03c4\u03b5 \u03bc\u03b5\u03c4\u03ac \u03b1\u03c0\u03cc \u03b4\u03b9\u03ac\u03c3\u03c4\u03b7\u03bc\u03b1 >1 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b1\u03c2 \u2014 \u03c4\u03bf \u03c6\u03b1\u03b9\u03bd\u03cc\u03bc\u03b5\u03bd\u03bf \u03c4\u03b7\u03c2 \u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b4\u03cc\u03c3\u03b7\u03c2 \u03b5\u03c0\u03b9\u03c3\u03c4\u03c1\u03ad\u03c6\u03b5\u03b9.<\/p>\n

        Practical Considerations for Hytrin<\/h2>\n
          \n
        • Once-daily dosing<\/strong> is a practical advantage over immediate-release prazosin; patients tolerate the regimen better.<\/li>\n
        • \u03a3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03c7\u03b1\u03bb\u03b1\u03c1\u03ae\u03c2 \u03af\u03c1\u03b9\u03b4\u03b1\u03c2<\/strong> — warn the ophthalmologist of any terazosin (or other alpha-blocker) exposure before cataract surgery.<\/li>\n
        • \u039c\u03b7 \u03b5\u03c0\u03b9\u03bb\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae<\/strong> alpha-1 blockade — tamsulosin and silodosin are more prostate-selective (alpha-1A subtype) and cause less orthostatic hypotension. Use terazosin where coexisting hypertension gives the systemic alpha-1 blockade a secondary benefit.<\/li>\n
        • Generic terazosin is inexpensive<\/strong> — the molecule is long off-patent; branded Hytrin reflects provenance rather than superior product.<\/li>\n
        • PDE-5 inhibitor caution<\/strong> — maintain a 4-6 hour gap between terazosin and sildenafil\/tadalafil\/vardenafil; additive hypotension is severe.<\/li>\n<\/ul>\n

          \u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n

          \u03a3\u03c5\u03c7\u03bd\u03ac (>1%):<\/strong><\/p>\n

            \n
          • \u0396\u03ac\u03bb\u03b7, \u03bf\u03c1\u03b8\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03cc\u03c4\u03b1\u03c3\u03b7<\/strong> (dose-limiting; worst on initiation)<\/li>\n
          • Asthenia, fatigue<\/strong><\/li>\n
          • \u039a\u03b5\u03c6\u03b1\u03bb\u03b1\u03bb\u03b3\u03af\u03b1<\/strong><\/li>\n
          • \u03a3\u03c5\u03bc\u03c6\u03cc\u03c1\u03b7\u03c3\u03b7 \u03c1\u03b9\u03bd\u03ce\u03bd<\/strong><\/li>\n
          • \u03a0\u03b5\u03c1\u03b9\u03c6\u03b5\u03c1\u03b9\u03ba\u03cc \u03bf\u03af\u03b4\u03b7\u03bc\u03b1<\/strong><\/li>\n
          • Somnolence<\/strong><\/li>\n
          • \u03a0\u03b1\u03bb\u03bc\u03bf\u03af<\/strong> (\u03b1\u03bd\u03c4\u03b1\u03bd\u03b1\u03ba\u03bb\u03b1\u03c3\u03c4\u03b9\u03ba\u03ae \u03c4\u03b1\u03c7\u03c5\u03ba\u03b1\u03c1\u03b4\u03af\u03b1)<\/li>\n
          • \u0391\u03bd\u03b1\u03b4\u03c1\u03bf\u03bc\u03b9\u03ba\u03ae \u03b5\u03ba\u03c3\u03c0\u03b5\u03c1\u03bc\u03ac\u03c4\u03b9\u03c3\u03b7<\/strong> (less than with tamsulosin)<\/li>\n
          • \u03a0\u03c1\u03b9\u03b1\u03c0\u03b9\u03c3\u03bc\u03cc\u03c2<\/strong> (\u03c3\u03c0\u03ac\u03bd\u03b9\u03b1)<\/li>\n<\/ul>\n

            \u03a3\u03c0\u03ac\u03bd\u03b9\u03b1 \u03b1\u03bb\u03bb\u03ac \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ac \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac:<\/strong><\/p>\n

              \n
            • \u03a3\u03c5\u03b3\u03ba\u03bf\u03c0\u03ae \u03bc\u03b5 \u03b1\u03c0\u03ce\u03bb\u03b5\u03b9\u03b1 \u03c3\u03c5\u03bd\u03b5\u03af\u03b4\u03b7\u03c3\u03b7\u03c2<\/strong> \u03c3\u03c4\u03b7\u03bd \u03c0\u03c1\u03ce\u03c4\u03b7 \u03b4\u03cc\u03c3\u03b7 \u03ae \u03b3\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03c4\u03b9\u03c4\u03bb\u03bf\u03b4\u03cc\u03c4\u03b7\u03c3\u03b7 \u2014 \u03c7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7 \u03c0\u03c1\u03b9\u03bd \u03c4\u03bf\u03bd \u03cd\u03c0\u03bd\u03bf\u00b7 \u03b5\u03bd\u03b7\u03bc\u03b5\u03c1\u03ce\u03c3\u03c4\u03b5 \u03c1\u03b7\u03c4\u03ac \u03c4\u03bf\u03bd \u03b1\u03c3\u03b8\u03b5\u03bd\u03ae.<\/li>\n
            • \u03a0\u03c1\u03b9\u03b1\u03c0\u03b9\u03c3\u03bc\u03cc\u03c2<\/strong> \u2014 \u03b5\u03c0\u03b5\u03af\u03b3\u03bf\u03c5\u03c3\u03b1 \u03bf\u03c5\u03c1\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03c0\u03b1\u03c1\u03b1\u03c0\u03bf\u03bc\u03c0\u03ae \u03b3\u03b9\u03b1 \u03c3\u03c4\u03cd\u03c3\u03b7 >4 \u03c9\u03c1\u03ce\u03bd.<\/li>\n
            • \u03a3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03c7\u03b1\u03bb\u03b1\u03c1\u03ae\u03c2 \u03af\u03c1\u03b9\u03b4\u03b1\u03c2 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7\u03bd \u03b5\u03b3\u03c7\u03b5\u03af\u03c1\u03b7\u03c3\u03b7<\/strong> \u2014 \u03bc\u03c0\u03bf\u03c1\u03b5\u03af \u03bd\u03b1 \u03c0\u03c1\u03bf\u03ba\u03b1\u03bb\u03ad\u03c3\u03b5\u03b9 \u03b5\u03c0\u03b9\u03c0\u03bb\u03bf\u03ba\u03ad\u03c2 \u03c3\u03b5 \u03b5\u03c0\u03ad\u03bc\u03b2\u03b1\u03c3\u03b7 \u03ba\u03b1\u03c4\u03b1\u03c1\u03c1\u03ac\u03ba\u03c4\u03b7\u00b7 \u03b5\u03bd\u03b7\u03bc\u03b5\u03c1\u03ce\u03c3\u03c4\u03b5 \u03c4\u03bf\u03bd \u03bf\u03c6\u03b8\u03b1\u03bb\u03bc\u03af\u03b1\u03c4\u03c1\u03bf.<\/li>\n
            • \u03a0\u03b1\u03c1\u03b1\u03b4\u03bf\u03be\u03b9\u03ba\u03ae \u03b1\u03ba\u03c1\u03ac\u03c4\u03b5\u03b9\u03b1 \u03bf\u03cd\u03c1\u03c9\u03bd \u03c3\u03b5 \u03b3\u03c5\u03bd\u03b1\u03af\u03ba\u03b5\u03c2<\/strong> (\u03c3\u03c0\u03ac\u03bd\u03b9\u03b1\u00b7 \u03b1\u03c0\u03bb\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03c4\u03bf\u03c5 \u03c4\u03cc\u03bd\u03bf\u03c5 \u03c4\u03b7\u03c2 \u03bf\u03c5\u03c1\u03bf\u03b4\u03cc\u03c7\u03bf\u03c5 \u03ba\u03cd\u03c3\u03c4\u03b7\u03c2 \u03bb\u03cc\u03b3\u03c9 \u03b1\u03c0\u03bb\u03bf\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2).<\/li>\n
            • \u0395\u03be\u03ac\u03c1\u03b8\u03c1\u03c9\u03c3\u03b7 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae\u03c2 \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1\u03c2<\/strong> \u2014 \u03b1\u03bd\u03b7\u03c3\u03c5\u03c7\u03af\u03b1 \u03ba\u03bb\u03ac\u03c3\u03b7\u03c2 \u03b1\u03c0\u03cc \u03c4\u03b7 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7 ALLHAT\u00b7 \u03c0\u03c1\u03bf\u03c3\u03bf\u03c7\u03ae \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u039a\u0391.<\/li>\n
            • \u03a3\u03bf\u03b2\u03b1\u03c1\u03ae \u03c5\u03c0\u03bf\u03c4\u03b1\u03c3\u03af\u03b1 \u03bc\u03b5 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 PDE-5<\/strong> (\u03c3\u03b9\u03bb\u03b4\u03b5\u03bd\u03b1\u03c6\u03af\u03bb\u03b7, \u03c4\u03b1\u03b4\u03b1\u03bb\u03b1\u03c6\u03af\u03bb\u03b7, \u03b2\u03b1\u03c1\u03b4\u03b5\u03bd\u03b1\u03c6\u03af\u03bb\u03b7) \u2014 \u03b4\u03b9\u03b1\u03c4\u03b7\u03c1\u03ae\u03c3\u03c4\u03b5 \u03b4\u03b9\u03ac\u03c3\u03c4\u03b7\u03bc\u03b1 4-6 \u03c9\u03c1\u03ce\u03bd.<\/li>\n<\/ul>\n

              \u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n